Colon cancer is one of the most prevalent cancer for both men and women. It’s also very common cause of cancer-related deaths1 — yet no two colon cancer patients, or their treatment needs, are the same.
The Oncotype DX Colon Recurrence Score test is clinically validated to quantify the risk of recurrence of patients with anatomic stage II, MMR-P and stage III A/B colon cancers.2-5 The 12-gene genomic test (seven cancer-related genes and five reference genes) looks at the underlying biology of a patient’s tumor—so you can choose a treatment that fits their unique situation.
The only genomic test for colon cancer with Level 1 evidence, the Colon Recurrence Score test gives you information that clinical and pathologic factors alone can’t provide. Developed over the course of multiple collaborative studies with both anatomic stage II and stage III patients, no other colon cancer multi-gene test is backed by as much data.
Performed on a tumor sample collected during your patient’s resection, the test looks at the activity of 12 genes in the tumor. The results are quantitative, reproducible, and offer an individualized assessment of risk for patients with either anatomic stage II, MMR-P or stage III A/B colon cancers.2-5
The Recurrence Score results provide a precise estimate of the risk of recurrence for anatomic stage II, MMR-P and stage III A/B patients to help guide the most appropriate treatment decision.2-5
The Colon Recurrence Score report includes the “Recurrence Score result”, which is a number between 0-100. A low score means a lower chance of recurrence and a high score means a higher chance of recurrence.
Four validation studies—QUASAR, CALGB 9581, NSABP C-07, and SUNRISE—confirm that the Recurrence Score result predicts the risk of local recurrence.2-5 In addition, studies show that physicians often change treatment recommendations based on the test results.8-11
For more information about the test contact us.